uBiome Appoints Dr. Anders Cervin, MD, Acclaimed ENT and Sinonasal Disease Researcher, to its Medical Advisory Board

Share Article

The leader in microbial genomics appoints nasal and sinus microbiome researcher to its board of medical advisors.

"I am very excited to join uBiome as they take their expertise to the important airway microbiome. It is a great possibility for me to marry my experience in the airway microbiome with uBiome resources to target diagnostic and treatment challenges ..." - Dr. Cervin, MD

uBiome, the leader in microbial genomics, announces the addition of Dr. Anders Cervin, MD, Conjoint Professor Chair of Otolaryngology of the Royal Brisbane Clinical Unit in the Faculty of Medicine at The University of Queensland Australia, to its Medical Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Cervin will bring to uBiome expertise in treating chronic sinusitis and middle ear infection with probiotics. The appointment will help uBiome continue its advancement in human microbiome research.

“Dr. Cervin’s innovative treatments for sinonasal infections target maintaining health and understanding the cause of disease rather than merely treating the symptoms,” Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. “uBiome is looking forward to tapping into his expertise with his addition to the board of medical advisors.”

Dr. Cervin is a Garnett Passe and Rodney Williams Foundation Chair in Otolaryngology in the Royal Brisbane Clinical Unit of the Faculty of Medicine at the University of Queensland in Australia. His recent research addresses the role of probiotics in airway infection and inflammation and he has identified a number of bacterial strains that have the capability of interfering with the pathogenic bacteria common in chronic sinusitis as well as in recurrent middle ear infection (otitis media). Dr. Cervin has authored several book chapters and over 50 peer-reviewed articles.

About joining uBiome's Medical Advisory Board, Dr. Cervin said, “I am very excited to join uBiome as they take their expertise to the important airway microbiome. It is a great possibility for me to marry my experience in the airway microbiome with uBiome resources to target diagnostic and treatment challenges in chronic sinusitis, allergic rhinitis, asthma, and COPD.”

In addition to Dr. Cervin, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company’s Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children’s Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.

_____
About uBiome
Founded in 2012, uBiome is the leader in microbial genomics. The Company’s mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.

uBiome’s commercial products include SmartGut™, the world’s first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women’s health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.

uBiome’s platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.

Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

uBiome Public Relations
@uBiome
Follow >
Visit website